Alkermes orexin stimulant shows promise in early ADHD trial

Alkermes reported preliminary results for an experimental orexin-system stimulant in ADHD, showing promise. The data are early and not yet peer-reviewed; efficacy and safety remain unconfirmed. If validated, this could offer a novel non-amphetamine treatment option, but market impact is speculative at this stage.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works